


| 1:00pm – 1.20pm | Welcome & official opening |
|------------------|--|
| | Rosanne Hyland, Chief Operating Officer, AusBiotech |
| | Hon Joe Szakacs MP , Minister for Trade and Investment, Local Government and Veterans' Affairs, South Australian Government |
| 1.20pm – 1.40pm | Keynote |
| | Investing in health: an angel's journey |
| | The angel investor community is becoming increasingly sophisticated and is a serious source of capital, fueling the growth of startups and contributing to high growth sectors. The formation of an ecosystem of investors that have knowledge of the healthcare sector is a relatively recent development and creates more formal connections between entrepreneurs and angels. This session will cover recent developments in the angel investor community from the perspective of Medical Angels and provide guidance to companies on how to navigate the angel investor landscape and assess the right partners to work with. Chair: Rosanne Hyland, Chief Operating Officer, AusBiotech Dr. Amandeep Hansra, Lead Investor & Co-Founder, Medical Angels |
| 1.40 pm – 2.40pm | Investee presentations |
| | Chair: Rosanne Hyland, Chief Operations Officer, AusBiotech Dr Mary Beth Brinson, Chief Executive Officer, Cyban Dr Shieak Tzeng, Co-CEO & Founder, Wellumio Jack Brown, Corporate Development Director, LBT Innovations (ASX:LBT) Tom Spurling, Managing Director, AlphaRET (ASX:EYE) |
| 2.40pm – 3.00pm | Keynote |
| | Deep tech investing and its role in healthcare |
| | Deep tech has seen an exponential rise in past decade, with an increasing number of investors moving into the space. Deep tech's share of venture capital investment has remarkably doubled over the past decade, now accounting for 20% of the total, up from just 10% ten years earlier (source: Boston Consulting Group, November 2023). With a prime focus on developing technology solutions based on substantial mathematical, |
| | scientific or engineering challenges, deep tech is an umbrella definition that includes, amongst others, agri-tech, food tech, clean tech, artificial intelligence and machine learning. It also includes some life science companies, with the term applied to businesses whose objective is to find innovative solutions using novel technologies. |



| | In this keynote address, Alex Romero will discuss the deep tech healthcare ecosystem, the outstanding research emanating from Australia's laboratories, and our nation's potential as a global deep tech hub. Chair: Rosanne Hyland, Chief Operating Officer, AusBiotech Alex Romero, Associate, Main Sequence |
|-----------------|--|
| 3.00pm – 3.20pm | Afternoon tea |
| 3.20pm – 3.50pm | Panel discussion |
| | Ice melts, markets thaw: 2024 medtech investment insights |
| | As the market is emerging from its icy grip from the last couple of years, we'll navigate the current Australian and international investment landscape. Catering to both newcomers and specialists this session will highlight the hottest opportunities and areas to approach with caution, drawing from the experience of our seasoned panellists. We will explore what makes a successful investment, what's required on the journey and hear how they try to steer clear of potential treacherous terrain. Chair: Sarah Meibusch, Partner, OneVentures Panellists: Dr Chris Nave, Founding Partner and Managing Director, Brandon Capital Dr Steve Burnell, Managing Director, Tenmile Dr Fredrik Nyberg, Managing Director, MedTech Innovator Asia Pacific Rohan Gray, Med Tech, Artesian Venture Partners |
| 3.50pm – 4.50pm | Investee presentations |
| | Chair: Sarah Meibusch, Partner, OneVentures |
| | Tony Simula, Managing Director & Chief Executive Officer, TekCyte Mark Roe, Chief Executive Officer, Managing Director, Fusetec Dr Simon Graindorge, Chief Operating Officer, OncoRes Medical David Hoey, Chief Executive Officer, Vaxxas |
| 4.50pm – 5.10pm | Keynote |
| | Driving successful medtech internationalisation through medtech investing As a global healthcare investment firm with more than \$8 billion in funds under management, ARCHIMED is one of the latest international healthcare investors to set up shop in Australia. With a portfolio of 34 companies (25 active and 9 exists), ARCHIMED's investments span 7 key healthcare subsectors: biopharma products, medtech, in vitro diagnostics, consumer health, healthcare IT, life science tools and biological services, and pharma services. ARCHIMED invests between 10 million and 1 billion Euros in leading companies across Europe, North America, Latin America, and most recently APAC, with a focus on supporting small to mid-cap companies |



| | in their internationalisation efforts, capacity increase, product range expansion, and acquisitions. |
|-----------------|--|
| | Following investments, ARCHIMED typically focuses on growth and business development-related priorities, such as innovation, internationalisation, acquisitions or capacity expansion. |
| | In this keynote, hear from Rowena Gracey, Director, ARCHIMED, as she discusses Australia's reputation as a hotbed for innovation, ARCHIMED's healthcare investments that have successfully internationalised, and what could be done differently to help Australian innovations expand globally. |
| | Chair: Rhenu Bhuller, Global Investment Lead, AusBiotech |
| | Rowena Gray, Director, ARCHIMED |
| 5.10pm – 5:25pm | Keynote |
| | ASX Update: The why, when, how and who of listingand what comes after A quick blast of why list on ASX, when is the right time, how it works, who to connect with plus what ASX provides to support companies post listing to tell their story and reach investors. |
| | Chair: Rhenu Bhuller, Global Investment Lead, AusBiotech |
| | Ajita Tynan, Manager, Listed Company Services & Sasha Conoplia, Manager, Listings, ASX |
| 5.25pm – 5:30pm | Closing remarks |
| | Rosanne Hyland, Chief Operating Officer, AusBiotech |
| 5:30pm – 7.00pm | AusMedtech 2024 Welcome reception Sponsored by FB Rice |